Mirum Pharmaceuticals, Inc.
MIRM
Updated: 23/09/2026, 03:12:47
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
No summaries found.
- Share price
- $91.39
- Market cap
- $5.57B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Christopher Peetz
- Employees
- 433
- IPO date
- 18/07/2019
- Beta
- 0.491
- Last dividend
- $0.00
- Day range
- $90.55 – $92.82
- 52-week range
- $63.23 – $130.00
- 1-day performance
- -0.66%
- 1-year performance
- 44.53%
- Current drawdown (1Y)
- -29.70%
- CIK
- 0001759425
- CUSIP
- 604749101
- ISIN
- US6047491013
- Created
- 07/12/2025, 05:15:10
- Last update
- 23/09/2026, 03:12:47
Track Mirum Pharmaceuticals, Inc. with an AI analyst
See which prediction-market events move MIRM, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
Business Wire • STOCK • 30/05/2026, 14:00:00
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance
MarketBeat • STOCK • 27/05/2026, 09:09:41
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
Business Wire • STOCK • 21/05/2026, 10:05:00
Mirum Pharma: A Rare Disease Growth Story to Watch
MarketBeat • STOCK • 20/05/2026, 14:35:42
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
Business Wire • STOCK • 13/05/2026, 01:56:00
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 07/05/2026, 01:21:14
Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q1 Earnings
Zacks Investment Research • STOCK • 06/05/2026, 21:01:14
Mirum Pharmaceuticals (NASDAQ: MIRM) Surges on Positive Volixibat Clinical Trial Results and Analyst Price Target Hike
Market Data • Market Data • 05/05/2026, 05:07:57
Mirum Pharmaceuticals (NASDAQ: MIRM) Soars on Positive Volixibat Clinical Trial Results
Market Data • Market Data • 05/05/2026, 04:10:44
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Clinical Results in Primary Sclerosing Cholangitis and Hepatitis Delta Transcript
Seeking Alpha • STOCK • 04/05/2026, 22:43:41
Mirum's rare liver disease drug meets main goal in mid-stage study
Reuters • STOCK • 04/05/2026, 16:04:51
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
Business Wire • STOCK • 03/05/2026, 19:00:00